Search - tctmd.com

Displaying 401 - 420 of 483

Sort: Relevancy | Date

News Daily News

Xience V Noninferior to Cypher for Primary PCI

July 24, 2012

News Daily News

Reducir el Uso de SLF a la Mitad en Pacientes de Bajo Riesgo podría suponer un Ahorro de 200 millones de Dólares al Año

Yael L. Maxwell

July 11, 2012

News Daily News

Halving DES Use in Low-Risk Patients Could Save $200 Million Annually

Yael L. Maxwell

July 11, 2012

News Daily News

DES Show More Neoatherosclerosis Than BMS Over 4 Years

L.A. McKeown

July 05, 2012

News Conference News EuroPCR 2012

EuroPCR 2012: Biodegradable Devices, Imaging Take Center Stage

Caitlin E. Cox

May 22, 2012

News Conference News EuroPCR 2012

CIBELES: Xience Stands Up to Cypher for CTO PCI

Caitlin E. Cox

May 17, 2012

News Conference News EuroPCR 2012

Strong Showing for Bioabsorbable-Scaffold DES

Caitlin E. Cox

May 16, 2012

News Conference News EuroPCR 2012

Biolimus-Eluting Stents Perform Well in STEMI, Unselected Populations

Jason Kahn

May 15, 2012

Presentation Fellows 2012

Stent Restenosis and Thrombosis: Etiology, Treatment, and Outcomes

Presenter: Ajay Kirtane

April 22, 2012

Presentation GI2 2012

Drug-Eluting Balloon: Clinical Evidence for In-Stent Restenosis

Presenter: Marco V. Wainstein

April 12, 2012

Presentation GI2 2012

The Controversy: DES vs DEB for In-Stent Restenosis

Presenter: Pedro A. Lemos

April 11, 2012

Presentation GI2 2012

Focus on In-Stent Restenosis: Imaging to Guide the Best Treatment

Presenter: Jose Ribamar Costa

April 11, 2012

News Conference News ACC 2012

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

March 26, 2012

Presentation ACC 2012

A Double Blind Randomized Study to Evaluate the Efficacy of Bindarit in Preventing Coronary Stent Restenosis

Presenter: Antonio Colombo

March 25, 2012

News Conference News ACC 2012

Anti-inflammatory Lowers In-Stent Late Loss After BMS Implantation

March 24, 2012

News Daily News

El Celecoxib Aumenta la Eficacia de los SLF a un determinado Coste Clínico

March 15, 2012

News Daily News

Celecoxib Enhances DES Efficacy, But at Clinical Cost

March 15, 2012

News Daily News

Surgery Common, Safe After Coronary Stent Implantation

Jason Kahn

March 13, 2012

News Daily News

SES Effective for Both Focal, Diffuse DES Restenosis

March 13, 2012

News Daily News

El SLS es Efectivo contra la Reestenosis tanto Focal como Difusa del SLF

March 13, 2012

Advertisement

Xience V Noninferior to Cypher for Primary PCI

Reducir el Uso de SLF a la Mitad en Pacientes de Bajo Riesgo podría suponer un Ahorro de 200 millones de Dólares al Año

Halving DES Use in Low-Risk Patients Could Save $200 Million Annually

DES Show More Neoatherosclerosis Than BMS Over 4 Years

EuroPCR 2012: Biodegradable Devices, Imaging Take Center Stage

CIBELES: Xience Stands Up to Cypher for CTO PCI

Strong Showing for Bioabsorbable-Scaffold DES

Biolimus-Eluting Stents Perform Well in STEMI, Unselected Populations

Stent Restenosis and Thrombosis: Etiology, Treatment, and Outcomes

Drug-Eluting Balloon: Clinical Evidence for In-Stent Restenosis

The Controversy: DES vs DEB for In-Stent Restenosis

Focus on In-Stent Restenosis: Imaging to Guide the Best Treatment

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

A Double Blind Randomized Study to Evaluate the Efficacy of Bindarit in Preventing Coronary Stent Restenosis

Anti-inflammatory Lowers In-Stent Late Loss After BMS Implantation

El Celecoxib Aumenta la Eficacia de los SLF a un determinado Coste Clínico

Celecoxib Enhances DES Efficacy, But at Clinical Cost

Surgery Common, Safe After Coronary Stent Implantation

SES Effective for Both Focal, Diffuse DES Restenosis

El SLS es Efectivo contra la Reestenosis tanto Focal como Difusa del SLF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content